Bernstein Liebhard LLP, a nationally recognized investor rights law firm, has initiated an investigation into potential breaches of fiduciary duty by certain directors and officers of Phreesia, Inc. (NYSE: PHR). The probe seeks to determine whether Phreesia’s leadership fulfilled its obligations to shareholders and whether legal remedies may be available based on publicly available information. This development signals a significant legal risk for investors, particularly those holding shares prior to May 8, 2025.

The investigation focuses on whether company leadership acted in the best interests of shareholders. Bernstein Liebhard is reviewing public disclosures to assess if fiduciary duties were compromised. The firm emphasizes that current Phreesia shareholders should evaluate their legal standing in light of these allegations.

Shareholder Action Required

Bernstein Liebhard is urging specific groups of investors to take action. The firm has outlined criteria for shareholders who may have grounds for legal recourse:

Shareholders meeting these criteria are advised to visit the firm’s Phreesia Shareholder Investigation page or contact Investor Relations Manager Peter Allocco directly. Contact details include phone number (212) 951-2030 and email pallocco@bernlieb.com for confidential consultations.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP has represented investors in complex securities and shareholder litigation for more than three decades. Since 1993, the firm has recovered more than $3.5 billion for its clients. It has been retained by many of the nation’s largest public and private pension funds to monitor investments and pursue claims on behalf of investors.

The firm’s track record includes recognition on The National Law Journal’s "Plaintiffs’ Hot List" thirteen times. Additionally, it has been included in The Legal 500 for sixteen consecutive years, reflecting its longstanding commitment to protecting shareholder rights.

What This Means for Investors

The initiation of this investigation highlights growing scrutiny over corporate governance at Phreesia. For shareholders, the key implication is the potential for class-action litigation or derivative suits if breaches are substantiated. Investors who purchased shares before the specified date of May 8, 2025, face the highest exposure. The firm’s statement serves as both a warning and an invitation for affected parties to consolidate their claims. While no formal complaint has been filed, the active investigation suggests that Bernstein Liebhard believes there is merit in exploring legal avenues against Phreesia’s leadership. Investors should monitor subsequent filings with the New York Stock Exchange and relevant courts for further developments.

Investors in Phreesia, Inc. are facing a July 13, 2026 deadline to seek appointment as lead plaintiff in a securities class action lawsuit. Pomerantz LLP reminds purchasers of the company's common stock between May 8, 2025, and March 30, 2026, inclusive, of the upcoming deadline. The lawsuit alleges that defendants made false and misleading statements regarding the company's business and financial outlook, specifically concealing deteriorating demand and reduced visibility in its Network Solutions segment and overstating the benefits of the AccessOne acquisition.

Allegations and Core Claims

The complaint asserts that Phreesia failed to disclose that pharmaceutical marketing commitments within its Network Solutions segment were weakening and that the company was experiencing reduced visibility into future spending commitments from pharmaceutical manufacturers. Defendants provided positive statements while concealing material adverse facts concerning the true state of Phreesia's slowing demand. Network Solutions clients were committing lower spending levels for the second half of fiscal year 2027 than anticipated, and increasing variability in revenue forecasting placed the company's fiscal year 2027 revenue guidance and long-term growth outlook at risk.

Guidance Revision and Market Reaction

On March 30, 2026, Phreesia announced significantly reduced revenue growth projections for fiscal year 2027. The company cut its guidance to $510 million to $520 million, a reduction of up to $49 million from the prior range of $545 million to $559 million issued on December 8, 2025. The company attributed the shortfall to "shorter visibility into spending commitments" from certain pharmaceutical manufacturers and weaker pharmaceutical marketing commitments. On this news, Phreesia's stock price fell approximately 27%, declining from a closing price of $11.41 per share on March 30, 2026, to $8.38 per share on March 31, 2026.

The following table contrasts the fiscal 2027 projections made in December 2025 with the revised figures issued in March 2026:

Class Period and Deadlines

The relevant dates for the securities class action are outlined below:

How to Participate

To join the Phreesia class action or to serve as lead plaintiff, investors must move the Court no later than July 13, 2026. Investors may contact Danielle Peyton at Pomerantz LLP at newaction@pomlaw.com or 646-581-9980, toll-free at 888.4-POMLAW, Ext. 7980. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Investors may also remain an absent class member, and eligibility to recover losses is based on purchase dates during the class period, not on current share ownership.